However, adiponectin may be negatively associated with body mass (i.e., body weight and BMI) [36], and recent papers have shown that individuals with obesity have lower levels [37,38], which therefore may explain its negative impact on bone in this population. Here, ADIPOQ is linked to obesity disorder.